Highlights Disc Medicine, Inc.

Equities

IRON

US2546041011

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
28.53 ^USD	+2.48%		+4.51%	-50.61%

Apr. 08	Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	MT
Apr. 02	Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Disc Medicine Trial of Light Sensitivity Treatment Achieves Primary Goal, But Misses Secondary Endpoint; Wedbush Cuts Price Target -- Shares Plunge	Apr. 01	MT
Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria	Apr. 01	CI
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia	Feb. 20	MT
Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease	Feb. 20	CI
Disc Medicine Says Potential Blood Disease Treatment Gets FDA Orphan Drug Designation	Feb. 09	MT
Disc Medicine Gets Orphan Drug Designation for Blood-Disorder Treatment	Feb. 09	DJ
Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera	Feb. 09	CI
Disc Presents Initial Positive Data from Ongoing Phase 1B/2 Trial of Disc-0974 in Patients with Myelofibrosis (Mf) and Anemia At the 65Th American Society of Hematology Annual Meeting	Dec. 11	CI
Disc Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Disc Medicine, Inc. Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers	23-10-03	CI
Arix Bioscience boosts net value, CEO jumping ship for PureTech Health	23-09-27	AN
Disc Medicine Gets FDA Fast Track Designation for MWTX-003 in Polycythemia Vera Treatment	23-09-20	MT
Disc Medicine Opco Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia	23-07-27	CI
Disc Medicine, Inc. Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria at European Hematology Association 2023 Congress	23-06-09	CI
Disc Medicine Opco Inc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria at European Hematology Association 2023 Congress	23-05-11	CI
Disc Medicine Opco Inc Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Disc Medicine, Inc.

Equities

IRON

US2546041011

Highlights

Filters